22.25
-1.26 (-5.34%)
| 前收盘价格 | 23.50 |
| 收盘价格 | 23.30 |
| 成交量 | 149,344 |
| 平均成交量 (3个月) | 797,635 |
| 市值 | 724,199,616 |
| 市盈率 (P/E TTM) | 17.52 |
| 预期市盈率 (P/E Forward) | 3.43 |
| 价格/销量 (P/S) | 1.01 |
| 股市价格/股市净资产 (P/B) | 2.34 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业毛利率 | 6.61% |
| 营业利益率 (TTM) | 13.71% |
| 稀释每股收益 (EPS TTM) | 1.22 |
| 季度收入增长率 (YOY) | 22.70% |
| 季度盈利增长率 (YOY) | -91.30% |
| 总债务/股东权益 (D/E MRQ) | 411.94% |
| 流动比率 (MRQ) | 1.08 |
| 营业现金流 (OCF TTM) | 198.44 M |
| 杠杆自由现金流 (LFCF TTM) | 341.32 M |
| 资产报酬率 (ROA TTM) | 7.95% |
| 股东权益报酬率 (ROE TTM) | 19.23% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Collegium Pharmaceutical, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 3.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 相对估值 | -5.0 |
| 财务健康 | 2.5 |
| AI Insight | NA |
| 平均 | 1.06 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 1.69% |
| 机构持股比例 | 117.12% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合